Table 3.

−491 A→T allele and genotype distributions in patients with AD and control subjects by center and odds ratios for developing AD according to the −491 AA genotype adjusted for sex, age, and center

Location of centerAllele frequencyGenotype distribution (%)OR (95% CI) AA vs AT+TT
NATAAATTT
OR = odds ratio.
Finland
    AD cases1090.820.1874 (0.68)31 (0.28)4 (0.04)0.8 (0.5–1.4)
    Controls1880.830.17135 (0.72)46 (0.24)7 (0.04)p < 0.5
UK
    AD cases2750.870.13210 (0.76)58 (0.21)7 (0.03)1.7 (1.3–2.6)
    Controls2030.800.20128 (0.63)68 (0.34)7 (0.03)p < 0.009
France
    AD cases6750.870.13510 (0.76)149 (0.22)16 (0.02)1.4 (1.1–1.9)
    Controls6570.820.18449 (0.68)184 (0.28)24 (0.04)p < 0.003
Spain
    AD cases1160.890.1194 (0.81)18 (0.16)4 (0.03)3.4 (1.9–6.1)
    Controls1330.760.2474 (0.55)53 (0.40)6 (0.05)p < 0.0001
Minnesota, USA
    AD cases2960.860.14220 (0.74)69 (0.23)7 (0.02)1.6 (1.1–2.2)
    Controls4630.800.20302 (0.65)140 (0.30)21 (0.05)p < 0.008
St. Louis, Missouri, USA
    AD cases2610.900.10212 (0.81)45 (0.17)4 (0.02)2.6 (1.8–3.9)
    Controls2820.790.21175 (0.62)98 (0.35)9 (0.03)p < 0.0001
Total
    AD cases1,7320.870.131320 (0.76)370 (0.22)42 (0.02)1.7 (1.5–1.9)
    Controls1,9260.810.191263 (0.65)589 (0.30)74 (0.04)p < 0.0001